share_log

CASI Pharmaceuticals Analyst Ratings

CASI Pharmaceuticals Analyst Ratings

CASI 製藥分析師評級
Benzinga ·  2023/08/14 18:35
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/14/2023 329.18% HC Wainwright & Co. → $10 Reiterates Buy → Buy
05/22/2023 329.18% HC Wainwright & Co. → $10 Reiterates Buy → Buy
11/16/2022 329.18% BTIG $21 → $10 Maintains Buy
11/15/2022 329.18% HC Wainwright & Co. $12 → $10 Maintains Buy
08/15/2022 415.02% HC Wainwright & Co. $3 → $12 Maintains Buy
06/03/2022 801.29% BTIG $4 → $21 Maintains Buy
05/16/2022 28.76% HC Wainwright & Co. $4 → $3 Maintains Buy
05/18/2021 71.67% BTIG → $4 Initiates Coverage On → Buy
05/14/2021 71.67% HC Wainwright & Co. $3.5 → $4 Maintains Buy
04/26/2021 63.09% Mizuho → $3.8 Initiates Coverage On → Buy
10/23/2020 114.59% Oppenheimer → $5 Initiates Coverage On → Outperform
03/24/2020 50.21% HC Wainwright & Co. $7 → $3.5 Maintains Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
08/14/2023 329.18% HC Wainwright & Co. → 10 美元 重申 購買 → 購買
05/22/2023 329.18% HC Wainwright & Co. → 10 美元 重申 購買 → 購買
11/16/2022 329.18% BTIG 21 美元 → 10 美元 維護 購買
11/15/2022 329.18% HC Wainwright & Co. 12 美元 → 10 美元 維護 購買
08/15/2022 415.02% HC Wainwright & Co. 3 美元 → 12 美元 維護 購買
06/03/2022 801.29% BTIG 4 美元 → 21 美元 維護 購買
05/16/2022 28.76% HC Wainwright & Co. 4 美元 → 3 美元 維護 購買
05/18/2021 71.67% BTIG → 4 美元 啓動覆蓋開啓 → 購買
05/14/2021 71.67% HC Wainwright & Co. 3.5 美元 → 4 美元 維護 購買
04/26/2021 63.09% 瑞穗 → 3.8 美元 啓動覆蓋開啓 → 購買
2020 年 10 月 23 日 114.59% 奧本海默 → 5 美元 啓動覆蓋開啓 → 跑贏大盤
2020 年 3 月 24 日 50.21% HC Wainwright & Co. 7 美元 → 3.5 美元 維護 購買

What is the target price for CASI Pharmaceuticals (CASI)?

CASI Pharmicals(CASI)的目標價格是多少?

The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $10.00 expecting CASI to rise to within 12 months (a possible 329.18% upside). 5 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年8月14日公佈了CASI Pharmicals(納斯達克股票代碼:CASI)的最新目標股價。這家分析公司將目標股價定爲10.00美元,預計CASI將在12個月內升至10.00美元(可能上漲329.18%)。去年有5家分析公司公佈了評級。

What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?

CASI Pharmicals(CASI)的最新分析師評級是多少?

The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals reiterated their buy rating.

CASI Pharmicals(納斯達克股票代碼:CASI)的最新分析師評級由HC Wainwright & Co. 提供,CASI Pharmicals重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?

CASI Pharmicals(CASI)的下一個分析師評級將在何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.

分析師在進行了廣泛的研究(包括瀏覽公開財務報表、與CASI Pharmicals的高管和客戶交談以及聽取業績電話會議)後得出股票評級。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。CASI Pharmicals的最新評級是在2023年8月14日提交的,因此您應該預計下一個評級將在2024年8月14日左右公佈。

Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?

分析師對CASI Pharmicals(CASI)的評級是否正確?

While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a reiterated with a price target of $0.00 to $10.00. The current price CASI Pharmaceuticals (CASI) is trading at is $2.33, which is within the analyst's predicted range.

儘管評級是主觀的,將會發生變化,但最新的CASI Pharmicals(CASI)評級得到了重申,目標股價爲0.00美元至10.00美元。CASI Pharmicals(CASI)目前的交易價格爲2.33美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論